 <h1>Kadcyla Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ado-trastuzumab emtansine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ado-trastuzumab emtansine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Kadcyla.</p><h2>In Summary</h2><p><b>Common side effects of Kadcyla include:</b> increased serum bilirubin, increased serum transaminases, cough, decreased platelet count, dyspnea, fatigue, fever, peripheral neuropathy, and thrombocytopenia. <b>Other side effects include:</b> chills.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ado-trastuzumab emtansine: intravenous powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>Do not substitute ado-trastuzumab emtansine with or for trastuzumab. Hepatotoxicity, liver failure, reductions in left ventricular ejection fraction, and death have occurred in ado-trastuzumab emtansine-treated patients. Monitor hepatic function and left ventricular function before beginning treatment and before each dose. Modify, hold, or discontinue treatment as necessary. Exposure to ado-trastuzumab emtansine during pregnancy can result in embryo-fetal harm. Advise patients of these risks and the need for effective contraception.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ado-trastuzumab emtansine (the active ingredient contained in Kadcyla) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking ado-trastuzumab emtansine:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bladder pain</li>
<li>bleeding gums</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>burning, numbness, tingling, or painful sensations</li>
<li>chills</li>
<li>cough</li>
<li>decreased urine</li>
<li>difficult or labored breathing</li>
<li>difficult, burning, or painful urination</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>mood changes</li>
<li>muscle pain or cramps</li>
<li>nausea</li>
<li>nervousness</li>
<li>nosebleeds</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>rapid weight gain</li>
<li>seizures</li>
<li>slow or fast heartbeat</li>
<li>sore throat</li>
<li>stomach pain</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unsteadiness or awkwardness</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
<li>dilated neck veins</li>
<li>extreme tiredness or weakness</li>
<li>general feeling of discomfort or illness</li>
<li>irregular breathing</li>
<li>skin rash</li>
<li>thickening of bronchial secretions</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Dark urine</li>
<li>general feeling of tiredness or weakness</li>
<li>light-colored stools</li>
<li>stomach bloating</li>
<li>vomiting blood</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>confusion</li>
<li>decreased awareness or responsiveness</li>
<li>depression</li>
<li>hostility</li>
<li>irritability</li>
<li>itching</li>
<li>joint pain, stiffness, or swelling</li>
<li>loss of consciousness</li>
<li>muscle twitching</li>
<li>severe sleepiness</li>
<li>stomach tenderness or cramps</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ado-trastuzumab emtansine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>change in taste</li>
<li>constipation</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>heartburn</li>
<li>indigestion</li>
<li>lack or loss of strength</li>
<li>loss of taste</li>
<li>muscle stiffness</li>
<li>stomach discomfort or upset</li>
<li>swelling or inflammation of the mouth</li>
<li>trouble sleeping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Burning, dry, or itching eyes</li>
<li>discharge or excessive tearing</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ado-trastuzumab emtansine: intravenous powder for injection</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Left ventricular dysfunction, hypertension, peripheral edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (12%)</p>
<p><b>Common</b> (1% to 10%): Pruritus, alopecia, nail disorder, palmar-plantar erythrodysesthesia syndrome, urticaria<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (40%), constipation (24%), vomiting (20%), diarrhea (20%), dry mouth (16%), abdominal pain (16%), stomatitis (15%), stomatitis</p>
<p><b>Common</b> (1% to 10%): Dyspepsia, gingival bleeding<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (12%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Hemorrhage (35%), thrombocytopenia (25%), anemia (15%), hemorrhage</p>
<p><b>Common</b> (1% to 10%): Neutropenia, leucopenia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Transaminases increased (12%)</p>
<p><b>Common</b> (1% to 10%):</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatotoxicity, hepatic failure, nodular regenerative hyperplasia, portal hypertension</p>
<p><b>Rare</b> (0.01% to 0.1%): Portal hypertension, hepatic failure, nodular regenerative hyperplasia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Immunogenicity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypokalemia (11%)</p>
<p><b>Common</b> (1% to 10%): Blood alkaline phosphatase increased<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (36%), arthralgia (19%), myalgia (13%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (28%), peripheral neuropathy (23%), asthenia, chills</p>
<p><b>Common</b> (1% to 10%): Dizziness, dysgeusia, memory impairment<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Dry eye, conjunctivitis, blurred vision, lacrimation increased<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (37%), pyrexia (23%), asthenia (16%), chills (10%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (12%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Epistaxis (24%), cough (20%), dyspnea (13%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Pneumonitis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Injection site extravasation, infusion-related reactions<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Kadcyla (ado-trastuzumab)." Genentech, South San Francisco, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Kadcyla (ado-trastuzumab emtansine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: HER2 inhibitors</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kadcyla &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer, Metastatic</li>
<li>Breast Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ado-trastuzumab emtansine: intravenous powder for injection</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Left ventricular dysfunction, hypertension, peripheral edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (12%)</p><p><b>Common</b> (1% to 10%): Pruritus, alopecia, nail disorder, palmar-plantar erythrodysesthesia syndrome, urticaria<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (40%), constipation (24%), vomiting (20%), diarrhea (20%), dry mouth (16%), abdominal pain (16%), stomatitis (15%), stomatitis</p><p><b>Common</b> (1% to 10%): Dyspepsia, gingival bleeding<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (12%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Hemorrhage (35%), thrombocytopenia (25%), anemia (15%), hemorrhage</p><p><b>Common</b> (1% to 10%): Neutropenia, leucopenia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Transaminases increased (12%)</p><p><b>Common</b> (1% to 10%):</p><p><b>Uncommon</b> (0.1% to 1%): Hepatotoxicity, hepatic failure, nodular regenerative hyperplasia, portal hypertension</p><p><b>Rare</b> (0.01% to 0.1%): Portal hypertension, hepatic failure, nodular regenerative hyperplasia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Immunogenicity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypokalemia (11%)</p><p><b>Common</b> (1% to 10%): Blood alkaline phosphatase increased<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (36%), arthralgia (19%), myalgia (13%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (28%), peripheral neuropathy (23%), asthenia, chills</p><p><b>Common</b> (1% to 10%): Dizziness, dysgeusia, memory impairment<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Dry eye, conjunctivitis, blurred vision, lacrimation increased<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (37%), pyrexia (23%), asthenia (16%), chills (10%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (12%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Epistaxis (24%), cough (20%), dyspnea (13%)</p><p><b>Uncommon</b> (0.1% to 1%): Pneumonitis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Injection site extravasation, infusion-related reactions<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Kadcyla (ado-trastuzumab)." Genentech, South San Francisco, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about Kadcyla (ado-trastuzumab emtansine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: HER2 inhibitors</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kadcyla &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer, Metastatic</li>
<li>Breast Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>